ESMO 2023: Pembrolizumab With Concurrent Chemoradiotherapy Improves Cervical Cancer Outcomes
Sixty-eight percent of patients who received the treatment were cancer-free after two years
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.